Vidofludimus calcium (IMU-838)
Relapsing-Remitting Multiple Sclerosis (RRMS)
Key Facts
About Immunic
Immunic is focused on developing next-generation, orally available small molecule therapies that aim to address the underlying mechanisms of chronic inflammatory and autoimmune diseases with high unmet need. The company's strategy centers on its lead asset, vidofludimus calcium (IMU-838), a selective oral immunomodulator targeting DHODH, which is in Phase 3 for multiple sclerosis and Phase 2 for ulcerative colitis and Crohn's disease. With a public listing and a diversified pipeline, Immunic aims to bring novel, convenient treatment options to patients suffering from debilitating autoimmune conditions.
View full company profileAbout Immunic
Immunic is focused on developing next-generation, orally available small molecule therapies that aim to address the underlying mechanisms of chronic inflammatory and autoimmune diseases with high unmet need. The company's strategy centers on its lead asset, vidofludimus calcium (IMU-838), a selective oral immunomodulator targeting DHODH, which is in Phase 3 for multiple sclerosis and Phase 2 for ulcerative colitis and Crohn's disease. With a public listing and a diversified pipeline, Immunic aims to bring novel, convenient treatment options to patients suffering from debilitating autoimmune conditions.
View full company profileAbout Immunic
Immunic is focused on developing next-generation, orally available small molecule therapies that aim to address the underlying mechanisms of chronic inflammatory and autoimmune diseases with high unmet need. The company's strategy centers on its lead asset, vidofludimus calcium (IMU-838), a selective oral immunomodulator targeting DHODH, which is in Phase 3 for multiple sclerosis and Phase 2 for ulcerative colitis and Crohn's disease. With a public listing and a diversified pipeline, Immunic aims to bring novel, convenient treatment options to patients suffering from debilitating autoimmune conditions.
View full company profileAbout Immunic
Immunic is focused on developing next-generation, orally available small molecule therapies that aim to address the underlying mechanisms of chronic inflammatory and autoimmune diseases with high unmet need. The company's strategy centers on its lead asset, vidofludimus calcium (IMU-838), a selective oral immunomodulator targeting DHODH, which is in Phase 3 for multiple sclerosis and Phase 2 for ulcerative colitis and Crohn's disease. With a public listing and a diversified pipeline, Immunic aims to bring novel, convenient treatment options to patients suffering from debilitating autoimmune conditions.
View full company profile